{"id":18375,"date":"2023-05-26T10:37:00","date_gmt":"2023-05-26T02:37:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18375"},"modified":"2025-01-06T18:16:33","modified_gmt":"2025-01-06T10:16:33","slug":"beigene-presents-groundbreaking-clinical-data-at-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18375","title":{"rendered":"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting"},"content":{"rendered":"\n

China-based BeiGene (NASDAQ: BGNE<\/a>, HKG: 6160<\/a>, SHA: 688235<\/a>) announced the presentation of new data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights the range of BeiGene\u2019s research expertise and the productivity of one of the industry\u2019s largest research and development teams. The results include data for BeiGene\u2019s cornerstone therapies, Brukinsa (zanubrutinib) and tislelizumab, as well as early results for BeiGene\u2019s OX40 agonist and BCL-2 inhibitor.<\/p>\n\n\n\n

Tislelizumab’s Latest Clinical Status: RATIONALE-301 Analysis<\/strong>
In a risk factor analysis of RATIONALE-301, a Phase III study comparing tislelizumab to sorafenib as a first-line treatment for unresectable hepatocellular carcinoma, tislelizumab showed numerically longer median overall survival (OS) in several biomarker subgroups. In a European\/North American (EU\/NA) subgroup analysis, tislelizumab demonstrated a numerically longer median OS, median duration of response, and a higher objective response rate (ORR) compared to sorafenib. Additionally, tislelizumab had a lower incidence of grade \u22653 treatment-emergent adverse events (TEAEs), grade \u22653 treatment-related TEAEs (TRAEs), and TRAEs leading to discontinuation.<\/p>\n\n\n\n

BRUKINSA’s Updated Analysis in ROSEWOOD Study<\/strong>
An updated analysis of the ROSEWOOD study showed that BRUKINSA in combination with obinutuzumab demonstrated clinically meaningful activity and a manageable safety profile in patients with heavily pretreated relapsed\/refractory (R\/R) follicular lymphoma (FL). BeiGene will detail the trial design of its ongoing Phase III MAHOGANY study of BRUKINSA plus obinutuzumab versus lenalidomide plus rituximab in R\/R FL or marginal zone lymphoma during the Trials in Progress session.<\/p>\n\n\n\n

Early Study Results for OX40 Agonist and BCL-2 Inhibitor<\/strong>
BeiGene\u2019s investigational BGB-A445, a novel monoclonal antibody OX40 agonist, is being studied as a single agent or in combination with tislelizumab in patients with advanced solid tumors. First-in-human results presented at ASCO showed that BGB-A445 monotherapy or in combination with tislelizumab was generally well-tolerated and demonstrated preliminary antitumor activity. The dose expansion phase is currently enrolling patients into non-small cell lung cancer and head and neck squamous cell carcinoma cohorts.<\/p>\n\n\n\n

BGB-11417, a potent and highly selective BCL-2 inhibitor, showed that single agent treatment was well tolerated at all tested doses up to 640 mg\/d in B-cell malignancies, with no dose-dependent toxicity increase. BGB-11417 monotherapy also showed promising initial efficacy results in R\/R chronic lymphocytic leukemia\/small lymphocytic lymphoma, with patients achieving responses at lower dose levels.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,185,2092,16,17,847,846,3046,18,848],"class_list":["post-18375","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-beigene","tag-beone-medicines","tag-cancer","tag-clinical-trial-results","tag-hkg-6160","tag-nasdaq-bgne","tag-nasdaq-onc","tag-pd-1-l1","tag-sha-688235"],"yoast_head":"\nBeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights the range of BeiGene\u2019s research expertise and the productivity of one of the industry\u2019s largest research and development teams. The results include data for BeiGene\u2019s cornerstone therapies, Brukinsa (zanubrutinib) and tislelizumab, as well as early results for BeiGene\u2019s OX40 agonist and BCL-2 inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18375\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18375\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-26T02:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T10:16:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18375#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18375\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting\",\"datePublished\":\"2023-05-26T02:37:00+00:00\",\"dateModified\":\"2025-01-06T10:16:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18375\"},\"wordCount\":394,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"BeiGene\",\"BeOne Medicines\",\"Cancer\",\"Clinical trial results\",\"HKG: 6160\",\"NASDAQ: BGNE\",\"NASDAQ: ONC\",\"PD-1\\\/L1\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18375#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18375\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18375\",\"name\":\"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-05-26T02:37:00+00:00\",\"dateModified\":\"2025-01-06T10:16:33+00:00\",\"description\":\"China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights the range of BeiGene\u2019s research expertise and the productivity of one of the industry\u2019s largest research and development teams. The results include data for BeiGene\u2019s cornerstone therapies, Brukinsa (zanubrutinib) and tislelizumab, as well as early results for BeiGene\u2019s OX40 agonist and BCL-2 inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18375#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18375\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18375#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting - Insight, China's Pharmaceutical Industry","description":"China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights the range of BeiGene\u2019s research expertise and the productivity of one of the industry\u2019s largest research and development teams. The results include data for BeiGene\u2019s cornerstone therapies, Brukinsa (zanubrutinib) and tislelizumab, as well as early results for BeiGene\u2019s OX40 agonist and BCL-2 inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18375","og_locale":"en_US","og_type":"article","og_title":"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18375","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-05-26T02:37:00+00:00","article_modified_time":"2025-01-06T10:16:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18375#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18375"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting","datePublished":"2023-05-26T02:37:00+00:00","dateModified":"2025-01-06T10:16:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18375"},"wordCount":394,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","BeiGene","BeOne Medicines","Cancer","Clinical trial results","HKG: 6160","NASDAQ: BGNE","NASDAQ: ONC","PD-1\/L1","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18375#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18375","url":"https:\/\/flcube.com\/?p=18375","name":"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-05-26T02:37:00+00:00","dateModified":"2025-01-06T10:16:33+00:00","description":"China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights the range of BeiGene\u2019s research expertise and the productivity of one of the industry\u2019s largest research and development teams. The results include data for BeiGene\u2019s cornerstone therapies, Brukinsa (zanubrutinib) and tislelizumab, as well as early results for BeiGene\u2019s OX40 agonist and BCL-2 inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18375#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18375"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18375#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18375"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18375\/revisions"}],"predecessor-version":[{"id":18376,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18375\/revisions\/18376"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}